CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species;” Believed to Be Longest Administration (Over Seven Years) of Monoclonal Antibody Monotherapy for HIV in People to Date

On April 12, 2022, CytoDyn Inc. (OTCQB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140, Vyrologix), a CCR5 antagonist with the potential for multiple therapeutic indications, announced the publication of a peer-reviewed research paper entitled “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab In Two Species” in the open-access journal PLOS Pathogens.